高血压合并急性脑梗死患者测定凝血、抗凝和纤溶指标的临床意义

The clinical significance of coagulation and fibrinolysis markers in hypertensive patients complicated with cerebral infarction

目的分析高血压病及合并急性脑梗死患者凝血、纤溶系统分子标志物指标的变化及意义,为临床早期诊治提供客观依据。方法检测100例高血压病患者、100例高血压病合并急性脑梗死患者及100名健康对照者血浆内皮素-1(ET-1)、血小板α-颗粒膜蛋白(GMP-140)、11-去氢血栓烷B2(11-DH-TXB2)、纤维蛋白原(FIB)、组织型纤溶酶原激活剂(t-PA)及纤溶酶原激活剂抑制物-1(PAI-1)含量,并进行分析与评价。结果高血压病患者、高血压病合并急性脑梗死患者血浆ET-1、GMP-140、11-DH-TXB2、FIB、t-PA、PAI-1含量均明显高于正常对照者,差异有统计学意义(P<0.01)。结论高血压病患者存在明显的凝血及纤溶功能失衡,这与其病情进展、急性脑梗死的发生密切相关,早期检测、早期防治具有重要的临床意义。

Objective To observe the changs of coagulation and fibrinolysis markers in hypertensive patients complicated with cerebral infarction, and its clinical significanse. Methods Endothelin-1 （ET-1）, platelet α-granule membrane glycoproein （GMP） -140,11 -dehydrothromboxane B2 （ 11 -DH-TXB2 ）, fibrinogen （ FIB ）, tissue-type plasminogen activator（t-PA） and plasminogen activator inhibitor-1 （PAI-1） were measured in 100 hypertensive patients, 100 hypertensive patients complicated with cerebral infarction and 100 normal controls. Results Plasma levels of ET-1, GMP-140, 11-DH-TXB2, FIB, t-PA and PAI-1 were found significantly higher in hypertensive patients complicated with cerebral infarction and hypertensive patients. There was significant difference between test groups and normal group（ P 〈 0.01 ）. Conclusions There is abnormal coagulation and fibrinolysis in hypertensive patients which is related to cerebral infarction. Appropriate treatment should be targeted on above abnormality.